Home > Oncology > The EFFORT needed to overcome PARP resistance in ovarian cancer

The EFFORT needed to overcome PARP resistance in ovarian cancer

Presented By
Dr. Shannon Neville Westin, University of Texas, MD Anderson Center
Journal
Physician's Weekly
Conference
ASCO 2021
Trial
Phase 2, EFFORT
Adavosertib with or without olaparib demonstrated clinical activity with a manageable toxicity profile in patients with PARPi-resistant ovarian cancer, regardless of BRCA status. Medicom’s journalist speaks with Dr. Shannon Neville Westin (Dept. Gynecologic Oncology and Reproductive Medicine, the University of Texas, MD Anderson Center) about the new phase 2 study, which was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, held virtually 4-10 June, 2021 [1]. The phase 2 EFFORT study (EFFicacy Of adavosertib in parp ResisTance: A randomized two-arm non-comparative phase 2 study of adavosertib with or without olaparib in women with PARP-resistant ovar...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on